Pharma Aids Limited (DSE:PHARMAID)
Bangladesh · Delayed Price · Currency is BDT 505.60
-7.20 (-1.40%)
At close: Nov 12, 2026
Pharma Aids Ratios and Metrics
Market cap in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 1,577 | 1,864 | 1,671 | 2,086 | 2,467 | 2,543 | |
Market Cap Growth | 1.94% | 11.54% | -19.89% | -15.46% | -2.98% | 104.82% |
Enterprise Value | 1,534 | 1,842 | 1,651 | 2,039 | 2,459 | 2,502 |
Last Close Price | 505.60 | 597.30 | 532.40 | 661.81 | 781.79 | 800.73 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 18.02 | 21.29 | 26.18 | 34.09 | - | 73.14 |
PS Ratio | 3.11 | 3.67 | 3.81 | 4.95 | 8.00 | 7.87 |
PB Ratio | 3.10 | 3.66 | 3.86 | 6.08 | 8.66 | 8.25 |
P/TBV Ratio | 3.10 | 3.66 | 3.86 | 6.08 | 8.66 | 8.25 |
P/FCF Ratio | 28.07 | 33.16 | - | 92.27 | 487.65 | 87.25 |
P/OCF Ratio | 20.58 | 24.32 | 42.02 | 91.53 | 339.47 | 75.13 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 3.02 | 3.63 | 3.77 | 4.84 | 7.97 | 7.74 |
EV/EBITDA Ratio | 12.58 | 15.10 | 18.36 | 22.34 | 134.45 | 40.46 |
EV/EBIT Ratio | 13.79 | 16.55 | 19.79 | 24.18 | 230.56 | 46.32 |
EV/FCF Ratio | 27.29 | 32.77 | - | 90.23 | 485.99 | 85.84 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.06 | 0.05 | 0.04 | 0.00 |
Debt / EBITDA Ratio | 0.12 | 0.12 | 0.30 | 0.20 | 0.63 | 0.02 |
Debt / FCF Ratio | 0.26 | 0.26 | - | 0.80 | 2.27 | 0.03 |
Net Debt / Equity Ratio | -0.08 | -0.08 | 0.04 | -0.04 | -0.01 | -0.08 |
Net Debt / EBITDA Ratio | -0.36 | -0.36 | 0.18 | -0.16 | -0.20 | -0.39 |
Net Debt / FCF Ratio | -0.77 | -0.77 | -0.93 | -0.64 | -0.72 | -0.82 |
Asset Turnover | 0.81 | 0.81 | 0.83 | 0.98 | 0.81 | 0.89 |
Inventory Turnover | 4.88 | 4.88 | 4.88 | 4.92 | 4.27 | 4.26 |
Quick Ratio | 1.60 | 1.60 | 1.33 | 1.36 | 1.77 | 2.50 |
Current Ratio | 3.00 | 3.00 | 3.33 | 3.06 | 3.26 | 4.32 |
Return on Equity (ROE) | 18.58% | 18.58% | 16.46% | 19.50% | -2.15% | 11.60% |
Return on Assets (ROA) | 11.06% | 11.06% | 9.83% | 12.24% | 1.75% | 9.35% |
Return on Invested Capital (ROIC) | 19.19% | 19.51% | 16.65% | 20.03% | -2.34% | 12.62% |
Return on Capital Employed (ROCE) | 20.70% | 20.70% | 19.20% | 24.60% | 3.70% | 17.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | 5.55% | 4.70% | 3.82% | 2.93% | -0.26% | 1.37% |
FCF Yield | 3.56% | 3.02% | -1.04% | 1.08% | 0.21% | 1.15% |
Dividend Yield | 0.59% | - | 0.56% | 0.37% | 0.13% | 0.61% |
Payout Ratio | 11.07% | 11.07% | 12.01% | 7.90% | - | 72.69% |
Buyback Yield / Dilution | 0.02% | 0.00% | - | - | - | - |
Total Shareholder Return | 0.61% | - | 0.56% | 0.37% | 0.13% | 0.61% |